As of May 27, 2025, Relmada Therapeutics Inc (RLMD) reports a Current Ratio of 4.45.
Current Ratio assesses a company's ability to pay short-term debts by comparing liquid assets to liabilities, with higher ratios signaling better financial health.
Historical Trend of Relmada Therapeutics Inc's Current Ratio
Over recent years, Relmada Therapeutics Inc's Current Ratio has shown significant volatility. The table below summarizes the historical values:
| Date | Current Ratio |
|---|---|
| 2024-12-31 | 4.45 |
| 2023-12-31 | 8.00 |
| 2022-12-31 | 12.23 |
| 2021-12-31 | 14.79 |
| 2020-12-31 | 9.37 |
This slight downward trend highlights how Relmada Therapeutics Inc manages its short-term assets and liabilities over time.
Comparing Relmada Therapeutics Inc's Current Ratio to Peers
To better understand Relmada Therapeutics Inc's position, it's useful to compare its Current Ratio against industry peers. Below are selected comparisons:
| Company | Current Ratio |
|---|---|
| Relmada Therapeutics Inc (RLMD) | 4.45 |
| Zevra Therapeutics Inc (KMPH) | 27.20 |
| Oramed Pharmaceuticals Inc (ORMP) | 25.19 |
| Fulcrum Therapeutics Inc (FULC) | 22.63 |
| CymaBay Therapeutics Inc (CBAY) | 10.96 |
| Milestone Pharmaceuticals Inc (MIST) | 9.10 |
Compared to its competitors, Relmada Therapeutics Inc's Current Ratio is among the highest compared to peers, indicating strong short-term financial flexibility but potentially excess cash that could be invested.